Camostat for COVID-19: real-time meta-analysis of 16 studies (Version 6)

Significantly lower risk is seen for mortality and recovery. 3 studies from 3 independent teams in 3 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 18% [-2‑34%] lower risk, without reaching statistical significance. Results are similar for peer-reviewed studies and worse for Randomized Controlled Trials.

Control Camostat

5 RCTs with 828 patients have not reported results (up to 5 years late).

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.